SGX943

North JR, Takenaka S, Rozek A, Kielczewska A, Opal S, Morici L, Finlay BB, Schaber CJ, Straube R, Donini O. A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy. J Biotech 2016; 226: 24-34.

Donini O, Morici L. Innate Defense Regulators as Treatment for Meliodosis. Presentation at 2015 ASM Biodefense and Emerging Diseases Research Meeting. February 9-11, 2015.

Kim JY, Ozato K. 2009. The sequestosome 1/p62 attenuates cytokine gene expression in activated macrophages by inhibiting IFN regulatory factor 8 and TNF receptor-associated factor 6/NF-kappaB activity. J Immunol 182: 2131-40

Moscat J, Diaz-Meco MT. 2009. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 137: 1001-4

Wuthiekanun, V., S. J. Peacock. 2006. Management of Melioidosis. Expert Rev Anti Infect Ther 4: 445-455

U.S. Department of Health and Human Services. 2012. 2012 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy.

Tangsudjai S, Pudla M, Limposuwan K, Woods DE, Sirisinha S, Utaisincharoen P. 2010. Involvement of the MyD88-independent pathway in controlling the intracellular fate of Burkholderia pseudomallei infection in the mouse macrophage cell line RAW 264.7. Microbiol Immunol 54: 282-90

CDC: Centers for Disease Control and Prevention. 2012. Melioidosis - risk of exposure. Accessed March 26, 2013

Peacock, S. J., D. Limmathurotsakul, Y. Lubell, G. C. Koh, L. J. White, N. P. Day, and R. W. Titball. 2012. Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PLoS Negl Trop Dis 6:e1488.

Inglis, TJJ., O'Reilly, L., Merritt, A. J., Levy, A., Heath, C. 2011. The Aftermath of the Western Australian Melioidosis Outbreak. Am J Trop Med Hyg 84(6): 851–857.